Compare · OWLT vs TMO
OWLT vs TMO
Side-by-side comparison of Owlet Inc. (OWLT) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OWLT and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $222.03B, about 1557.0x OWLT ($142.6M).
- TMO has been more active in the news (16 items in the past 4 weeks vs 9 for OWLT).
- TMO has more recent analyst coverage (25 ratings vs 6 for OWLT).
- Company
- Owlet Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $142.6M
- $222.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2020
- News (4w)
- 9
- 16
- Recent ratings
- 6
- 25
Owlet Inc.
Owlet, Inc. operates as a digital parenting platform in the United States. The company's platform focuses on giving real-time data and insights to parents. Its products include Owlet Monitor Duo that gets the snapshot of baby's wellbeing; Owlet Smart Sock that tracks baby's heart rate and oxygen while sleeping and get notifications if baby needs to be checked on; Owlet Cam, a smart HD video baby monitor; and Dream Lab, an online and personalized infant sleep solution. The company was founded in 2012 and is based in Lehi, Utah.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest OWLT
- Director Stoll Marc F was granted 45,781 shares (SEC Form 4)
- Director Burke Zane M was granted 45,781 shares, increasing direct ownership by 51% to 134,787 units (SEC Form 4)
- Director Durr Laura was granted 26,785 shares, increasing direct ownership by 27% to 127,454 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Owlet Inc.
- Owlet Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Owlet Inc.
- SEC Form SCHEDULE 13G filed by Owlet Inc.
- Owlet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Owlet Announces Second Quarter 2026 Financial Results
- Owlet to Report Second Quarter 2026 Financial Results on August 11, 2026
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)